ADC Therapeutics SA (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® (loncastuximab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE